CA-DENODO
1.12.2021 09:02:07 CET | Business Wire | Press release
Denodo , the leader in data virtualization, today revealed the findings of a new Total Economic Impact™ (TEI) study to demonstrate the tangible benefits of data virtualization using the Denodo Platform. The study, commissioned by Denodo and conducted by Forrester Consulting, quantified the financial impact of the solution and found Denodo customers achieved a return on investment of 408% and total economic benefits of a present value up to $6.8 million over three years.
The complete, complimentary study can be found here .
More specifically, the benefits to a blended organization that consists of long term Denodo customers include:
- 83% reduction in time-to-revenue
- 67% reduction in data preparation effort
- 65% decrease in delivery times over ETL
According to the TEI study, “Data fabric technology takes the data virtualization a step further by automating data management functions using artificial intelligence/machine learning (AI/ML) and providing additional semantic capabilities through data catalog, data preparation, and data modeling. This reduces the burden on IT and data engineering teams that traditionally leveraged ETL processes.”
The TEI study is a culmination of Forrester’s multi-step approach to evaluating the financial impact of the Denodo Platform by interviewing several of Denodo's longest standing customers. To better understand the benefits, costs, and risks associated with this investment, Forrester interviewed key decision-makers across four companies in different industries with experience using the Denodo Platform. The highlights from their investments include:
- Decrease in data delivery times over ETL: “Since deploying Denodo, we have gone anywhere from a couple of days or weeks to less than a day to deliver data sets.” - IT Manager, Manufacturing
- Improved operational efficiency enabled with data-driven decision-making: “From the [operations] perspective, being able to provide business users with the capability to start asking and answering questions themselves … it has really given us the ability to see around the corner. There is no way that my team, even if we dropped everything, would have been able to react to a situation like the pandemic as fast as we did without Denodo.” - VP of Data & Analytics, Real Estate
- Improved profit: “Let’s say it took our data science team three months to write this model for a project, and now we can get that down to one week, we are increasing the probability that the project succeeds as opposed to slowing it down and we can release our product sooner. These are multimillion dollar products, so even delaying them one day can be a million dollars or more in missed revenue.” – Director, Enterprise Architecture, Life Sciences Industry
- Reduced legacy integration costs & efficiency gain for data scientists: “In terms of reducing legacy spending, we’re probably saving $400,000 a year. The flip side of that is Denodo has allowed us to do a lot more so now, we’ve grown that footprint and we’ve replaced that $400,000 with a whole bunch of new things we can never do in the old world. More importantly, our data scientists no longer spend 30% of their time on data wrangling and data curation. They can now spend that time on modeling since we can logically model our data within Denodo.” - VP of Data & Analytics, Real Estate
Data virtualization helps organizations access data across disparate sources and deliver a unified view of the data faster, cheaper, and using fewer resources than traditional data integration approaches. Denodo’s logical data fabric approach goes beyond data virtualization, enabling organizations to effectively integrate and manage their data where it lives without replicating it, allowing both technical and non-technical users to quickly answer key business questions using a data-driven approach.
“With retention rates close to 95%, the Denodo Platform goes beyond every other data virtualization solution enabling organizations to connect to all of their data in real time at half the cost of traditional approaches,” said Ravi Shankar, senior vice president and chief marketing officer at Denodo. “We believe this comprehensive Forrester study demonstrates the power and ROI potential organizations can achieve by leveraging the Denodo Platform, as we help bridge the gap between IT and business.”
For more information, download the study here .
Please Tweet: News: @denodo delivers ROI of 408% according to new independent research study @forrester Total Economic Impact™ study showcases the benefits of Denodo’s #datavirtualization solution to create a logical #datafabric and how it enables customers to rapidly increase business agility and performance https://bit.ly/3xCkvZ4
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005060/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
